Now an Indian company working on the country’s first home-grown, potentially affordable Alzheimer’s drug Masupirdine (formerly SUVN 502) is raising hopes for 6.1 million senior citizens in India suffering from dementia. Hyderabad-based Suven Life Sciences (Suven) has started recruiting patients for the Phase 3 trial of this novel drug that could possibly slow cognitive decline.
The company’s stock surged nearly 9 per cent during the day’s trade on the BSE.
Alzheimer’s is a progressive neurological, degenerative disorder that causes the brain to shrink and the brain cells to die. According to a 2021 Lancet study on the burden of neurological